Pharmacokinetics of once-daily darunavir/ritonavir in second-line treatment in African children with HIV
Journal of Antimicrobial Chemotherapy · 04.11.2024 · 79 (11) · 2990-2998
DOI: 10.1093/jac/dkae319 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Antimicrobial Chemotherapy, online erschienen am 20.09.2024. Verfasst von Lufina Tsirizani und 18 weiteren Autor:innen. Beteiligte Einrichtung: Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa. Hauptthemen laut MEDLINE: Darunavir, Ritonavir, HIV Infections, Anti-HIV Agents. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: European and Developing Countries Clinical Trials Partnership, Research council of Norway, National Institute of Allergy and Infectious Diseases.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Background
Darunavir is a potent HIV protease inhibitor with a high barrier to resistance. We conducted a nested pharmacokinetic sub-study within CHAPAS-4 to evaluate darunavir exposure in African children with HIV, taking once-daily darunavir/ritonavir for second-line treatment.
Methods
We used data from the CHAPAS-4 pharmacokinetic sub-study treating children with once-daily darunavir/ritonavir (600/100 mg if 14–24.9 kg and 800/100 mg if ≥25 kg) with either tenofovir alafenamide fumarate (TAF)/emtricitabine (FTC), abacavir/lamivudine or zidovudine/lamivudine. Steady-state pharmacokinetic sampling was done at 0, 1, 2, 4, 6, 8, 12 and 24 hours after observed darunavir/ritonavir intake. Non-compartmental and population pharmacokinetic analyses were used to describe the data and identify significant covariates. Reference adult pharmacokinetic data were used for comparison. We simulated the World Health Organization (WHO) recommended 600/100 mg darunavir/ritonavir dose for the 25–34.9 kg weight band.
Results
Data from 59 children with median age and weight 10.9 (range 3.8–14.7) years and 26.0 (14.5–47.0) kg, respectively, were available. A two-compartment disposition model with transit absorption compartments and weight-based allometric scaling of clearance and volume best described darunavir data. Our population achieved geometric mean (%CV) darunavir AUC0–24h, 94.3(50) mg·h/L and Cmax, 9.1(35) mg/L, above adult reference values and Ctrough, 1.5(111) mg/L, like adult values. The nucleoside reverse-transcriptase inhibitor backbone was not found to affect darunavir concentrations. Simulated WHO-recommended darunavir/ritonavir doses showed exposures equivalent to adults. Higher alpha-1-acid glycoprotein increased binding to darunavir and decreased apparent clearance of darunavir.
Conclusions
Darunavir exposures achieved in our trial are within safe range. Darunavir/ritonavir can safely be co-administered with TAF/FTC. Both WHO-recommended 600/100 mg and CHAPAS-4 800/100 mg darunavir/ritonavir doses for the 25–34.9 kg weight band offer favourable exposures. The choice between them can depend on tablet availability.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa.
- Training and Research Unit of Excellence, Kamuzu University of Health Sciences, Blantyre, Malawi.
- Department of Pharmacy, Radboudumc Research Institute for Medical Innovation (RIMI), Radboud University Medical Center, Nijmegen, The Netherlands.
- Medical Research Council Clinical Trials Unit at University College London, London, UK.
- Department University Teaching Hospital, University of Lusaka, Lusaka, Zambia.
- Department of Paediatrics and Child Health, Clinical Research Centre, University of Zimbabwe, Faculty of Medicine and Health Sciences, Harare, Zimbabwe.
ORCID-Profile: Lufina Tsirizani, Alexander Szubert, Veronica Mulenga, Helen M McIlleron, Paolo Denti, Roeland E Wasmann, Angela Colbers
Förderung
- European and Developing Countries Clinical Trials Partnership
- Research council of Norway
- National Institute of Allergy and Infectious Diseases
- NIAID NIH HHS
- MRC core funding
- NIH HHS
- European Union
- National Institutes of Health
Zitieren
APA
Tsirizani, L., Mohsenian Naghani, S., Waalewijn, H., Szubert, A., Mulenga, V., Chabala, C., Bwakura-Dangarembizi, M., Chitsamatanga, M., Rutebarika, D. A., Musiime, V., Kasozi, M., Lugemwa, A., Monkiewicz, L. N., McIlleron, H. M., Burger, D. M., Gibb, D. M., Denti, P., Wasmann, R. E., & Colbers, A. (2024). Pharmacokinetics of once-daily darunavir/ritonavir in second-line treatment in African children with HIV. Journal of Antimicrobial Chemotherapy, 79(11), 2990-2998. https://doi.org/10.1093/jac/dkae319
Vancouver
Tsirizani L, Mohsenian Naghani S, Waalewijn H, Szubert A, Mulenga V, Chabala C, et al. Pharmacokinetics of once-daily darunavir/ritonavir in second-line treatment in African children with HIV. Journal of Antimicrobial Chemotherapy. 2024;79(11):2990-2998. doi:10.1093/jac/dkae319
BibTeX
@article{Tsirizani2024,
author = {Tsirizani, Lufina and Mohsenian Naghani, Shaghayegh and Waalewijn, Hylke and Szubert, Alexander and Mulenga, Veronica and Chabala, Chishala and Bwakura-Dangarembizi, Mutsa and Chitsamatanga, Moses and Rutebarika, Diana A and Musiime, Victor and Kasozi, Mariam and Lugemwa, Abbas and Monkiewicz, Lara N and McIlleron, Helen M and Burger, David M and Gibb, Diana M and Denti, Paolo and Wasmann, Roeland E and Colbers, Angela},
title = {Pharmacokinetics of once-daily darunavir/ritonavir in second-line treatment in African children with HIV},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2024},
volume = {79},
number = {11},
pages = {2990--2998},
doi = {10.1093/jac/dkae319}
}
EUVIMED